Success Metrics

Completion Rate
0%(0/1)
Active Trials
4(80%)
Terminated
1(20%)

Phase Distribution

Ph phase_2
3
60%
Ph phase_1
2
40%

Phase Distribution

2

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution5 total trials
Phase 1Safety & dosage
2(40.0%)
Phase 2Efficacy & side effects
3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

4

trials recruiting

Total Trials

5

all time

Status Distribution
Active(4)
Terminated(1)

Detailed Status

Active, not recruiting2
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
5
Active
4
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (40.0%)
Phase 23 (60.0%)

Trials by Status

active_not_recruiting240%
recruiting240%
terminated120%

Recent Activity

4 active trials
Showing 5 of 5
recruitingphase_2

Descartes-08 in Autoantibody Myositis

NCT07391605
recruitingphase_1

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

NCT07089121
active_not_recruitingphase_2

Descartes-08 for Patients With Systemic Lupus Erythematosus

NCT06038474
active_not_recruitingphase_2

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

NCT04146051
terminatedphase_1

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

NCT03448978

Clinical Trials (5)

Showing 5 of 5 trials
NCT07391605Phase 2

Descartes-08 in Autoantibody Myositis

Recruiting
NCT07089121Phase 1

Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders

Recruiting
NCT06038474Phase 2

Descartes-08 for Patients With Systemic Lupus Erythematosus

Active Not Recruiting
NCT04146051Phase 2

Descartes-08 CAR-T Cells in Generalized Myasthenia Gravis (MG)

Active Not Recruiting
NCT03448978Phase 1

Autologous CD8+ T-cells Expressing an Anti-BCMA CAR in Patients With Myeloma

Terminated

All 5 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
5